UPCOMING DEADLINES: The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of NWL, MOH, and FLKS
28 Jun 2018
NEW YORK, June 28, 2018 (GLOBE NEWSWIRE) -- The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff. Newell Brands Inc. (NYSE:NWL) Lead Plaintiff Deadline: August 20, 2018 Class Period: February 6, 2017 - January 24, 2018 Allegations: The Company’s retail channel was loaded with extremely high levels of unsold Newell product; contrary to defendants’ representations, the build-up of Newell inventory in the retail channel was due to Company-specific rather than macroeconomic reasons; as a result of the unusually high levels of unsold inventory in the retail channel, Newell was exposed to a heightened risk that it would experience slower sales growth in future periods; and undisclosed managerial and cultural differences in the legacy Newell and Jarden businesses had created significant discord that was having a material adverse effect on the Company’s operating performance. Get additional information: http://www.kleinstocklaw.com/pslra-c/newell-brands-inc?wire=3. Molina Healthcare, Inc. (NYSE:MOH) Lead Plaintiff Deadline: June 29, 2018 Class Period: October 31, 2014 - August 2, 2017 Allegations: Molina Healthcare made materially false and/or misleading statements or failed to disclose that: Molina's administrative infrastructure was never designed to handle the size and complexity of its rapid growth strategy; and (2) it failed to remediate systemic issues and costly disruptions with critical administrative infrastructure functions, including provider payment and utilization management. Get additional information: http://www.kleinstocklaw.com/pslra-c/molina-healthcare-inc-2?wire=3. Flex Pharma, Inc. (NASDAQ:FLKS) Lead Plaintiff Deadline: August 20, 2018 Class Period: November 6, 2017 - June 12, 2018 Allegations: The Company overstated the viability and approval prospects for its product candidate FLX-787 for the treatment of amyotrophic lateral sclerosis and Charcot-Marie-Tooth disease; and as a result, Flex Pharma's public statements were materially false and misleading at all relevant times. Get additional information: http://www.kleinstocklaw.com/pslra-c/flex-pharma-inc?wire=3. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. There is no cost or obligation to you. If you suffered a loss during the class period and wish to obtain additional information, please contact Joseph Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided. Joseph Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes. CONTACT:Joseph Klein, Esq.Empire State Building350 Fifth Avenue59th FloorNew York, NY 10118jk@kleinstocklaw.comTelephone: (212) 616-4899Fax: (347) 558-9665www.kleinstocklaw.com
Organizations
Targets
-Drugs
Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.